Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic renal anemia;~* continuous iv maintenance epoetin alfa therapy, with the same dosing interval during the previous month to and during SVP;~* regular hemodialysis for greater than or equal to (\>=) 3 months~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months~* poorly controlled hypertension requiring interruption of epoetin alfa treatment in previous 6 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A (Type: EXPERIMENTAL): Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).